ApprovedFDA approval

Jideytro (zidesamtinib)

Nuvalent (NUVL)

Marketer take

For ROS1-positive lung cancer after a prior ROS1 inhibitor, a small biomarker-defined group, so thoracic oncologists and testing labs are the audience and competing ROS1 brands should expect sequencing messages.

Sponsor company
Nuvalent (NUVL)
Indication
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
Therapeutic area
Oncology
Event
FDA approval
Date
Jul 22, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move